- トップ
- 研究業績
- Ishitsuka K, Yokoyama Y, Baba N, Matsuoka R, Sakamoto N, Sakamoto T, Kusakabe M, Kato T, Kurita N, Nishikii H, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Chiba S. Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. J Clin Exp Hematop 62(3):154-157, Sep 28, 2022 (doi: 10.3960/jslrt.21035.) Epub Jul 12, 2022
Ishitsuka K, Yokoyama Y, Baba N, Matsuoka R, Sakamoto N, Sakamoto T, Kusakabe M, Kato T, Kurita N, Nishikii H, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Chiba S. Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. J Clin Exp Hematop 62(3):154-157, Sep 28, 2022 (doi: 10.3960/jslrt.21035.) Epub Jul 12, 2022
2023/08/07
- 研究業績
- Ishitsuka K, Yokoyama Y, Baba N, Matsuoka R, Sakamoto N, Sakamoto T, Kusakabe M, Kato T, Kurita N, Nishikii H, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Chiba S. Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. J Clin Exp Hematop 62(3):154-157, Sep 28, 2022 (doi: 10.3960/jslrt.21035.) Epub Jul 12, 2022
« Tsuboi Y, Iimura Y, Matsumura F, Nanmoku T, Suma S, Matsuoka R, Nakag... | Takeda J, Yoshida K, Nakagawa MM, Nannya Y, Yoda A, Saiki R, Ochi Y, Zh... »
